2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12D.04 Treatment Pattern and Clinical Outcome in Chinese NSCLC Patients with MET Alterationwho Had Disease Progressionon EGFR-TKIs

EP.12D.04 Treatment Pattern and Clinical Outcome in Chinese NSCLC Patients with MET Alterationwho Had Disease Progressionon EGFR-TKIs

Back to course

Pdf Summary

The document reports on a study analyzing treatment patterns and clinical outcomes in Chinese patients with advanced non-small cell lung cancer (NSCLC) characterized by MET alterations, following disease progression on EGFR-TKIs (epidermal growth factor receptor tyrosine kinase inhibitors). MET amplification or overexpression (MET amp/OE) is identified as a common resistance mechanism to EGFR-TKIs. The document references the TATTON and SAVANNAH studies that demonstrated the potential effectiveness of combining MET inhibitors (METi) with EGFR-TKIs for these patients.<br /><br />In the study, 238 NSCLC patients with MET amp/OE were reviewed, and 32 who had progressed on EGFR-TKIs were further analyzed. Among these, the majority (96.88%) had adenocarcinoma, most were in stage IV cancer, and a significant number had brain metastases. The study identifies three main follow-up treatment strategies: METi plus EGFR-TKI combination therapy, chemotherapy, and other regimens including immunotherapy.<br /><br />The analysis covered 24 patients with follow-up data, focusing on objective response rate (ORR) and median time to treatment failure (mTTF). Patients receiving METi plus EGFR-TKI demonstrated an ORR of 54.55%, equalling that of those on chemotherapy-based regimens. However, the METi plus EGFR-TKI group showed a markedly improved mTTF of 9.5 months compared to 4.4 months for the chemotherapy group. Particularly, the combination of Savolitinib and Osimertinib showed promising results, with an ORR of 75% and mTTF of 12.8 months in the best-case scenarios, significantly outperforming the chemotherapy outcomes.<br /><br />Overall, the study highlights METi plus EGFR-TKI combinations as a promising treatment avenue with acceptable safety profiles for Chinese NSCLC patients with MET alterations post-EGFR-TKI progression. Future research directions include assessing the therapy's effectiveness across different patient subtypes and comparing results to first-line treatments.

Asset Subtitle

Xin Wang

Meta Tag

Speaker Xin Wang

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

NSCLC

MET alterations

EGFR-TKIs

MET amplification

MET inhibitors

adenocarcinoma

brain metastases

Savolitinib

Osimertinib

treatment outcomes